Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound

Mouse CD1 Plasma, Rat Plasma, and Pooled Human Plasma from Innovative Research were used in the following study:

Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound

Lara Pes, Stephan David Koester, Johannes Pall Magnusson, Serghei Chercheja, Federico Medda, Khalid Abu Ajaj, Didier Rognan, Steffen Daum, Friederike Inga Nollmann, Javier Garcia Fernandez, Patricia Perez Galan, Heidi-Kristin Walter, Anna Warnecke, Felix Kratz

Journal of Controlled Release
Volume 296, 28 February 2019, Pages 81-92

"... AE-KetoSulf07 and AE-Ester-Sulf07 are novel acid-sensitive albumin-binding prodrugs demonstrating tumor regressions in all of the evaluated human tumor xenograft models thus supporting the stratagem that albumin can be used as an effective drug carrier for the highly potent class of auristatins ... Pooled plasma (CD1 murine, rat and human) was purchased from Innovative Research, Inc. (Novi, MI, USA) ..."

Related products available from Innovative Research also include:

• All Animal Plasma Products
• All Human Plasma Products
• Human Cancer-State Products
• Innovative Grade US Origin Fetal Bovine Serum